Korneuburg, Austria, December 5, 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital again by EUR 83,750 to EUR 1,778,333 by issuing 83,750 new no-par value bearer shares against cash contributions (the “Second Capital Increase”). The new shares will be issued from the authorized capital 2024 under exclusion of statutory subscription rights of existing shareholders. A report on the intended exclusion of the subscription rights of existing shareholders (the “Report”) was published on the Company's website from November 28, 2024 onwards, and on the electronic announcement and information platform of the Federal Government of Austria ("EVI") on November 28, 2024. The issue price per new share is EUR 8 so that the total issue price amounts to EUR 670,000. The required Supervisory Board resolution for the Second Capital Increase under exclusion of statutory subscription rights can be passed no earlier than two weeks after publication of the Report. The Company had already provided information on a possible second capital increase in ad hoc announcements of September 2, September 15, September 18 and November 27, 2024.
All 83,750 new shares have been subscribed by a total of nine individually approached investors at these issue terms and conditions.
+++ End of ad-hoc announcement +++